ZZPZH(SH:600436) Zhong Zheng Wang·2026-01-27 13:14Core Viewpoint - The company has announced the initiation of Phase I clinical trials for its innovative drug PZH2113 capsules, targeting relapsed/refractory non-Hodgkin lymphoma, marking a significant advancement in its oncology portfolio [1][3]. Group 1: Clinical Development - PZH2113 capsules have completed the first subject enrollment in Phase I clinical trials, officially entering the clinical research phase [1]. - The drug is designed for relapsed/refractory non-Hodgkin lymphoma, specifically targeting diffuse large B-cell lymphoma, with a clinical trial approval expected by June 2024 [1][2]. - The Phase I trial consists of an open-label, non-randomized, multi-center design, divided into Part A (dose escalation and expansion) and Part B (cohort expansion) [1]. Group 2: Market Context - The incidence of non-Hodgkin lymphoma in China is on the rise, with over 90% of approximately 100,000 new cases of malignant lymphoma in 2020 being non-Hodgkin lymphoma [2]. - There is a significant unmet clinical need for effective treatments for relapsed/refractory non-Hodgkin lymphoma, as current first-line therapies have a 30%-40% recurrence rate [2]. - The global market for diffuse large B-cell lymphoma is projected to exceed $20 billion by 2030, indicating substantial market potential for new therapies [2]. Group 3: Strategic Implications - The entry of PZH2113 capsules into Phase I clinical trials represents a critical step in the company's strategy to enhance its oncology treatment offerings [3]. - Successful development and approval of PZH2113 could diversify the company's product line and strengthen its competitive position in the oncology market [3].